Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 15/06/2020

    German Federal Government invests 300 Million Euros in CureVac

    The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
  • Vaccine development - 02/06/2020 07777_de.jpg

    CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

    All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
  • Material research - 25/05/2020 Das Team der Yuri GmbH in Meckenbeuren

    Reaching up into weightlessness – a start-up that enables commercial research experiments in space

    Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
  • Prime Vector Technologies GmbH - 09/04/2020 Kleineres_Original_fuer_Kachel_Corona_AdobeStock_318040586_Kopie.jpg

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
  • Press release - 27/06/2019

    Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme

    Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/velabs-therapeutics-announces-eur3-million-series-b-financing-advance-its-functional-antibody-screening-programme
  • Company profile - 19/12/2018 The photo shows a lateral view of a typical printer with a red blister pack to symbolise the suitability of printers for the production of drugs.

    With DiHeSys into integrated digital healthcare

    The founders and partners of DiHeSys have big ambitions: "We have to build a complete ecosystem around the patient," says Dr. Markus Dachtler, managing director of DiHeSys. The company develops products and services for an industry in transition, provides answers to trends such as personalized medicine, 2D- and 3D-printing technologies and platform technologies. The company’s motto: no isolated solutions, but a comprehensive range of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/with-dihesys-into-integrated-digital-healthcare
  • Press release - 04/01/2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
  • Article - 18/10/2017 Two people in blue sterile clothing, wearing a face mask and a green hair cover, handling plastic tubes filtering the antibody solution under sterile conditions. Bags containing a red/transparent liquid are shown in the foreground.

    Testing a new antibody therapy for treating blood cancer

    The fight against acute myeloid leukaemia is a long one. Cancer cells that cause the disease to recur may remain despite initially successful destruction of the tumour with chemotherapy drugs. Now researchers from Tübingen have identified an antibody that could potentially prevent cancer recurrence.

    https://www.gesundheitsindustrie-bw.de/en/article/news/testing-a-new-antibody-therapy-for-treating-blood-cancer
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 20/06/2016 Photo showing a disk-shaped cartridge for use in a point-of-care system.

    New diagnostic tool for greater health safety when dealing with multidrug-resistant pathogens

    Infections with antibiotic-resistant bacteria and diseases such as breast or colon cancer are among the major causes of death worldwide. Early diagnosis is therefore key for the identification of people affected and for providing immediate therapy. The R&D service provider Hahn-Schickard and its partners are currently working on the development of a rapid and simple diagnostic system that can detect life-threatening infections and cancer at…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-diagnostic-tool-for-greater-health-safety-when-dealing-with-multidrug-resistant-pathogens
  • Press release - 03/11/2015 07777_de.jpg

    CureVac raises $110 Million in a private placement

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
  • Press release - 29/04/2015 The logo shows the words "cytena, Single Cells on Demand".

    cytena received EUR 1.1 million of seed capital from HTGF and a private investor

    cytena GmbH, headquartered in Freiburg, has developed a device called cy-Clone to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand its marketing and distribution activities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cytena-received-eur-11-million-of-seed-capital-from-htgf-and-a-private-investor
  • Article - 11/08/2014 The photo shows a bent circuit board, chip and electronics have adapted themselves to the shape of the board.<br />

    PRONTO develops microsystems for and with companies

    Since 2010, PRONTO, a project run by the MicroTEC Südwest cluster, has been focusing on the production of innovative microsystems for application in the medical and other sectors. PRONTO provides microsystems development support up to small-scale production. Customers who are seeking to implement their ideas into concrete microsystems solutions can count on the expertise and infrastructure of four institutes.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pronto-develops-microsystems-for-and-with-companies
  • Press release - 16/10/2013 20464_de.jpg

    BIOTECHNICA 2013 - Baden-Württemberg is a top life sciences spot.

    The BIOTECHNICA trade show rolled out the red carpet for its exhibitors. Over 10,000 visitors walked over the carpet to inspect the exhibits that were on display at the Baden-Württemberg booth. The impressive exhibits of the companies showed that Baden-Württemberg has many highly innovative SMEs in the life sciences field.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnica-2013-baden-wuerttemberg-is-a-top-life-sciences-spot
  • Article - 04/05/2013 19613_de.jpg

    Ionera – measuring tiny ion currents

    The identification and characterisation of individual DNA and protein molecules is gaining in importance. A method developed by Dr. Gerhard Baaken and Prof. Dr. Jan C. Behrends at the University of Freiburg has the potential to be used by scientists to analyse a large number of single molecules automatically using nanopores. The MECA (microelectrode cavity array) technology can be adapted to a broad range of different applications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ionera-measuring-tiny-ion-currents
  • Article - 17/12/2012 18923_de.jpg

    Medicyte GmbH – gold standard for human cells

    Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicyte-gmbh-gold-standard-for-human-cells
  • Article - 17/09/2012 17981_de.jpg

    Thomas Paulöhrl: spatially and temporally controlled light-induced reactions

    Thomas Paulöhrl, polymer chemist from the Karlsruhe Institute of Technology (KIT), was awarded the 2012 Lanxess Talent Award for his achievements in further developing light-induced click strategies that can now be used for generating various surface structures and three-dimensional frameworks. His Ph.D. thesis not only provides the basis for new ways to efficiently modify material, it also opens up new research opportunities in medical drug…

    https://www.gesundheitsindustrie-bw.de/en/article/news/thomas-pauloehrl-spatially-and-temporally-controlled-light-induced-reactions
  • Article - 17/09/2012 18052_de.jpg

    Alexander Wittemann: polymeric nanostructures as carriers of biomolecules

    Vesicles form naturally in cells and can do many things including transporting pharmaceutically active substances to tumours. However natural vesicles only have a short lifespan which can lead to the premature release of the drug enclosed within them. Alexander Wittemann a chemist at Konstanz University has successfully developed artificial biocompatible polymer vesicles with a much longer lifespan.

    https://www.gesundheitsindustrie-bw.de/en/article/news/alexander-wittemann-polymeric-nanostructures-as-carriers-of-biomolecules
  • Dossier - 24/05/2012 Lab-on-a-chip: The photo shows a small black plate with a yellow border and a network of microscopically small channels.<br />

    Biochips: microsystems technology for the life sciences

    Nanoscale robots and intelligent measurement systems in arteries, fingernail-sized DNA chips that can be used to analyze thousands of genes in tiny samples, intelligent DNA microsensors – the trend in the life sciences is moving towards miniaturization in all areas including electronics, sensor systems and the handling of liquids. Over the last few years, a research area with growing potential has developed at the interface of physics, the…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/biochips-microsystems-technology-for-the-life-sciences
  • Press release - 23/05/2012 Cellzome Logo

    GlaxoSmithKline to fully acquire Cellzome for 99 million U.S. dollar

    GlaxoSmithKline plc (GSK) announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/glaxosmithkline-to-fully-acquire-cellzome-for-99-million-u-s-dollar
  • Press release - 16/05/2012 In the picture is a big grey building behind green trees.

    OGpharma in China

    OGpharma (CEO: Dr. Wanzhou ZHAO) is a Contract Research Company (CRO) located in Nanjing’s Gulou Science Park. The company offers two services: a) contract research, and b) consulting service for international cooperation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ogpharma-in-china
  • Article - 25/07/2011 14858_de.jpg

    CellGenix GmbH – Cell therapy and all that is needed

    CellGenix was spun out of the Freiburg University Medical Centre around 17 years ago with the aim of cultivating and commercialising therapeutic cell material in compliance with high safety and quality standards. The Freiburg-based company has since become a leading manufacturer and supplier of cartilage cells and umbilical cord stem cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cellgenix-gmbh-cell-therapy-and-all-that-is-needed
  • Press release - 27/06/2011 14614_de.jpg

    NMI TT GmbH – creating value from research

    NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-gmbh-creating-value-from-research
  • Press release - 23/05/2011 14325_de.jpg

    Systems biology in Baden-Württemberg

    The emerging interdisciplinary field of systems biology is pursuing a completely new approach namely the description of the dynamic interplay of all the components of a biological system using mathematical models with the aim of obtaining a holistic view of the system under consideration. This new approach is expected to lead to new approaches for the treatment of diseases and for the industrial production of enzymes. With its three systems…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/systems-biology-in-baden-wuerttemberg

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search